[{"Physician_Profile_ID": "1171097", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "Merck Sharp & Dohme Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NJ", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000000053", "Total_Amount_of_Payment_USDollars": "81.60", "Date_of_Payment": "10/30/2013", "Form_of_Payment_or_Transfer_of_Value": "In-kind items and services", "Record_ID": "24481112", "Name_of_Associated_Covered_Drug_or_Biological1": "EMEND for Injection", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of In", "Research_Information_Link": "", "Context_of_Research": ""}, {"Physician_Profile_ID": "1171097", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "Merck Sharp & Dohme Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NJ", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000000053", "Total_Amount_of_Payment_USDollars": "81.60", "Date_of_Payment": "11/25/2013", "Form_of_Payment_or_Transfer_of_Value": "In-kind items and services", "Record_ID": "24481114", "Name_of_Associated_Covered_Drug_or_Biological1": "EMEND for Injection", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of In", "Research_Information_Link": "", "Context_of_Research": ""}, {"Physician_Profile_ID": "1171097", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "Merck Sharp & Dohme Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NJ", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000000053", "Total_Amount_of_Payment_USDollars": "81.60", "Date_of_Payment": "11/25/2013", "Form_of_Payment_or_Transfer_of_Value": "In-kind items and services", "Record_ID": "24481115", "Name_of_Associated_Covered_Drug_or_Biological1": "EMEND for Injection", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of In", "Research_Information_Link": "", "Context_of_Research": ""}, {"Physician_Profile_ID": "1171097", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "Merck Sharp & Dohme Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NJ", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000000053", "Total_Amount_of_Payment_USDollars": "81.60", "Date_of_Payment": "11/25/2013", "Form_of_Payment_or_Transfer_of_Value": "In-kind items and services", "Record_ID": "24481113", "Name_of_Associated_Covered_Drug_or_Biological1": "EMEND for Injection", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of In", "Research_Information_Link": "", "Context_of_Research": ""}, {"Physician_Profile_ID": "1171097", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "Merck Sharp & Dohme Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NJ", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000000053", "Total_Amount_of_Payment_USDollars": "73.50", "Date_of_Payment": "11/25/2013", "Form_of_Payment_or_Transfer_of_Value": "In-kind items and services", "Record_ID": "24481111", "Name_of_Associated_Covered_Drug_or_Biological1": "EMEND for Injection", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of In", "Research_Information_Link": "", "Context_of_Research": ""}, {"Physician_Profile_ID": "1171097", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "Merck Sharp & Dohme Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NJ", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000000053", "Total_Amount_of_Payment_USDollars": "48.47", "Date_of_Payment": "10/30/2013", "Form_of_Payment_or_Transfer_of_Value": "In-kind items and services", "Record_ID": "24481193", "Name_of_Associated_Covered_Drug_or_Biological1": "EMEND for Injection", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of In", "Research_Information_Link": "", "Context_of_Research": ""}, {"Physician_Profile_ID": "1171097", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "Merck Sharp & Dohme Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NJ", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000000053", "Total_Amount_of_Payment_USDollars": "13.60", "Date_of_Payment": "10/30/2013", "Form_of_Payment_or_Transfer_of_Value": "In-kind items and services", "Record_ID": "24481191", "Name_of_Associated_Covered_Drug_or_Biological1": "EMEND for Injection", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of In", "Research_Information_Link": "", "Context_of_Research": ""}, {"Physician_Profile_ID": "1171097", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "Merck Sharp & Dohme Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NJ", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000000053", "Total_Amount_of_Payment_USDollars": "13.60", "Date_of_Payment": "10/30/2013", "Form_of_Payment_or_Transfer_of_Value": "In-kind items and services", "Record_ID": "24481192", "Name_of_Associated_Covered_Drug_or_Biological1": "EMEND for Injection", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of In", "Research_Information_Link": "", "Context_of_Research": ""}]